Digest Réseau Comment ça marche
Réseau
/
Sociétés
Su
Non vérifié

Summit Therapeutics

Ce que nous écrivons

BiotechnologieIndustrie pharmaceutiqueMédecine - DiversOncologieSanté

45 communiqués de presse

Voir tous les communiqués de presse
02/10/2026
Marché du travail
Science
Médecine - Divers
Santé Publique
Biotechnologie
Industrie pharmaceutique
Santé
Oncologie
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
Source
Summit Therapeutics
Émetteur
Business Wire
1.00
0
28/09/2026
Marché du travail
Industrie
Science
Médecine - Divers
Biotechnologie
Santé
Industrie pharmaceutique
Santé Publique
Oncologie
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
Source
Summit Therapeutics
Émetteur
Business Wire
1.00
0
22/09/2026
Industrie
Événements
Science
Hygiène alimentaire
Médecine - Divers
Biotechnologie
Santé
Industrie pharmaceutique
Oncologie
HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026
Source
Summit Therapeutics
Émetteur
Business Wire
1.00
0
15/09/2026
Science
Biotechnologie
Industrie pharmaceutique
Oncologie
Santé Publique
Santé
Médecine - Divers
Événements
Industrie
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients
Source
Summit Therapeutics
Émetteur
Business Wire
1.00
0
13/09/2026
Oncologie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Marché du travail
Événements
Industrie
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China
Source
Summit Therapeutics
Émetteur
Business Wire
1.00
0
02/09/2026
Industrie
Science
Biotechnologie
Médecine - Divers
Santé Publique
Industrie pharmaceutique
Santé
Oncologie
Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China
Source
Summit Therapeutics
Émetteur
Business Wire
1.00
0
25/08/2026
Analyse de marché
Industrie
Science
Médecine - Divers
Santé Publique
Biotechnologie
Industrie pharmaceutique
Santé
Oncologie
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
Source
Summit Therapeutics
Émetteur
Business Wire
1.00
0
25/08/2026
Industrie
Biotechnologie
Santé Publique
Santé
Industrie pharmaceutique
Oncologie
Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
Source
Summit Therapeutics
Émetteur
Business Wire
1.00
0
12/08/2026
Industrie
Oncologie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
Source
Summit Therapeutics
Émetteur
Business Wire
1.00
0
05/08/2026
Analyse de marché
Industrie
Science
Médecine - Divers
Biotechnologie
Santé
Industrie pharmaceutique
Santé Publique
Oncologie
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
Source
Summit Therapeutics
Émetteur
Business Wire
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0